ANDREW PAUL PETERSON
Physical Therapy at Highland Ave, Madison, WI

5972982, Oct 26, 1999

Oct 7, 1997

8/946529

Haridasan K. Nair - Williamsville NY
Andrew C. Peterson - Madison WI
Friedrich Paltauf - Graz, AT
Albin Hermetter - Graz, AT
Rudolf Franzmair - Linz, AT

Clarion Pharmaceuticals Inc. - Madison WI

A61K 3141, A61K 31415, C07D24908, C07D23356

514383

Heteroaryl-substituted deoxy glycerols represented by the general Formulas Ia, Ib and Ic: ##STR1## wherein: X is oxygen (--O--) or sulfur (--S--); R is substituted or unsubstituted straight or branched chain C. sub. 1-30 alkyl or alkenyl, provided that a double bond of the alkenyl does not originate at the carbon atom bound to the X substituent; Het is a 5- to 9-membered heteroaryl mono- or bicyclic ring system having no more than 1 carbonyl carbon in the ring system, with 1 to 4 nitrogen atoms as the sole heteroatoms, one of which nitrogens is bonded to the glycero carbon; and Y is hydroxyl (--OH) or thiol (--SH), pharmaceutical compositions containing the same, and methods of using the compounds, are disclosed. The compounds exhibit antiviral and antibacterial activities.

5827836, Oct 27, 1998

Nov 15, 1996

8/749512

Andrew C. Peterson - Madison WI
Thaddeus P. Pruss - Madison WI
Parvin T. Yazdi - Madison WI

Clarion Pharmaceuticals Inc. - Madison WI

A61K 3166, C07F 910

514 77

Retinoyl substituted glycerophosphoethanolamines are disclosed having the general Formula I: ##STR1## wherein one of A, B or C is a fatty ether substituent, one is a natural or synthetic retinoid ester substituent, and one is a phosphoethanolamine substituent, provided that A, B and C are each a different substituent. The optical and geometric isomers of compounds of Formula I and the pharmaceutically acceptable salts of the compounds, including the isomers, are also disclosed. The compounds (including the isomers thereof) and salts of the invention exhibit anti-tumor, anti-psoriatic and anti-inflammatory activities.

5891881, Apr 6, 1999

Nov 21, 1997

8/976408

Haridasan K. Nair - Williamsville NY
Andrew C. Peterson - Madison WI

Clarion Pharmaceuticals Inc. - Madison WI

A61K 352, C07D47318, C07D47326, C07D23902, C07D24908, C07D23328

514261

Aminoheterocycle-substituted glycerols of Formula I are disclosed: ##STR1## wherein one of A, B or C is --X--R, wherein X is --O-- or --S--, and R is a substituted or unsubstituted C. sub. 12-24 alkyl or alkenyl, the substituent being one or more of halo, C. sub. 1-3 alkoxy or cyano, provided that a double bond of the alkenyl does not originate at the carbon atom bound to X; and another of A, B or C is an aminoheterocycle ring substituent --Het--NH. sub. 2, wherein Het is a 5 to 11-membered monocyclic, bicyclic or bicyclic fused heterocyclic ring moiety with at least 1 to 4 nitrogens atoms contained within the hetero cyclic moiety, one of which nitrogen atoms is bonded to the glycero carbon; and the remaining A, B, or C substituent is --OH. The compounds of Formula I, isomers, salts, pharmaceutical compositions and appliances incorporating the same, and methods of use thereof are also disclosed.

5691328, Nov 25, 1997

Aug 27, 1996

8/703447

Andrew C. Peterson - Madison WI
Parvin T. Yazdi - Madison WI

Clarion Pharmaceuticals Inc. - Madison WI

A61K 3159, C07C40100

514167

Certain phosphoethanolamine conjugates of vitamin D compounds are disclosed wherein the phosphoethanolamine moiety is bonded at the 3-position of the vitamin D moiety. The conjugates exhibit anti-tumor, anti-psoriatic and anti-inflammatory activities in addition to those activities associated with vitamin D. The invention embraces the novel compounds, pharmaceutical compositions thereof, and their methods of use.

5661138, Aug 26, 1997

Oct 3, 1996

8/726059

Andrew C. Peterson - Madison WI
Rudolf Franzmair - Linz, AT
Haridasan K. Nair - Madison WI

Clarion Pharmaceutical, Inc. - Madison WI

A61K 31685, C07F 910

514 77

Novel (o-acyl-p-N-acylamino-phenyl)-O-phosphoethanolamines and pharmaceutically acceptable salts thereof having anti-inflammatory activity, and pharmaceutical compositions containing same are disclosed. Certain novel intermediates are also disclosed.

5883084, Mar 16, 1999

Jun 8, 1998

/093128

Andrew C. Peterson - Madison WI
Thaddeus P. Pruss - Madison WI

Clarion Pharmaceuticals Inc. - Madison WI

A61K 31685, A61K 31355

514 78

Disclosed is a method of treating respiratory diseases comprising treating the lungs with an therapeutically-effective amount of. alpha. -tocopheryl-phosphocholine or a pharmaceutically-acceptable salt thereof, wherein the amount is administered is effective to make breathing easier.

5804569, Sep 8, 1998

Mar 14, 1997

8/818378

Andrew C. Peterson - Madison WI
Haridasan K. Nair - Madison WI

Clarion Pharmaceuticals Inc. - Madison WI

A61K 31685

514 77

Disclosed are the use of certain cycloalkyl- and aryl-phosphoethanolamines as anti-inflammatory, anti-arrhythmic and local anesthetic agents. These therapeutically active cycloalkyl- and aryl-phosphoethanolamines are of the general Formula I: R--O--PEA I wherein R is an unsubstituted or a substituted C. sub. 5-7 cycloalkyl or an unsubstituted or a substituted phenyl in which each substituent is hydrogen or an unsubstituted or substituted straight or branched C. sub. 1-4 alkyl or C. sub. 2-4 alkenyl, said substitution being one or more of C. sub. 1-4 alkoxy, halo or cyano; and --O--PEA represents a phosphoethanolamine substituent. Also disclosed are intermediates for producing Formula I compounds.

6177476, Jan 23, 2001

Aug 27, 1998

9/141061

Andrew C. Peterson - Madison WI
Thaddeus P. Pruss - Madison WI

Clarion Pharmaceuticals Inc. - Madison WI

A61K 3108

514722

A method of replenishing plasmalogens in mammals comprising treatment with a plasmalogen-replenishing-effective amount of one or more stantially pure monoethers of glycerols and their carboxylic acid ester derivatives of Formula I: ##STR1## wherein R is a C. sub. 12 -C. sub. 22 linear or branched alkyl or alkenyl group; and R. sup. 1 and R. sup. 2 are, each independently, hydrogen or an acyl moiety {--C(. dbd. O)--R. sup. 3 } wherein R. sup. 3 is a linear or branched C. sub. 1 -C. sub. 30 alkyl or alkenyl; and pharmaceutically-acceptable salts thereof, is disclosed. Nutritional supplements, dietary supplements and food additives comprising one or more substantially pure compounds of Formula I is also disclosed.